证券代码：002826 证券简称：易明医药 公告编号：2023-033 西藏易明西雅医药科技股份有限公司 关于举办 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2 出席本次网上业绩说明会的人员有：公司董事长、总经理许可先生；财务总 监周敏女士；独立董事肖兴刚先生；董事会秘书、副总经理李前进女士。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月8 日（星期一）12:00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集 专题页面进行提问。公司将在2022年度业绩说明会上，对投资者普遍关注的问题 进行回答。欢迎广大投资者积极参与！ （问题征集专题页面二维码） 特此公告。 1 西藏易明西雅医药科技股份有限公司 董事会 二〇二三年五月五日 西藏易明西雅医药科技股份有限公司（以下称"公司"）已于2023年4月27日 在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022年年度报告 ...

Financial Performance - The company's operating revenue for 2022 was CNY 856,734,308, representing an increase of 18.10% compared to CNY 725,459,075 in 2021[19] - The net profit attributable to shareholders for 2022 was CNY 44,135,409, a 3.91% increase from CNY 42,476,491 in 2021[19] - The net profit after deducting non-recurring gains and losses was CNY 39,487,468, up 2.21% from CNY 38,634,658 in 2021[19] - The total assets at the end of 2022 were CNY 1,018,204,646, reflecting a 23.50% increase from CNY 824,473,281 at the end of 2021[19] - The net assets attributable to shareholders increased by 3.89% to CNY 745,293,911 at the end of 2022 from CNY 717,389,579 at the end of 2021[19] - The basic earnings per share for 2022 were CNY 0.23, a 4.55% increase from CNY 0.22 in 2021[19] - The company achieved a revenue of 856.73 million yuan in 2022, representing an 18.10% increase year-over-year[49] - Net profit attributable to shareholders was 44.14 million yuan, reflecting a 3.91% growth compared to the previous year[49] - The company reported a total revenue of 1.5 billion yuan for the fiscal year 2022, representing a year-over-year increase of 15%[134] - The net profit for the year was 300 million yuan, which is a 20% increase compared to the previous year[134] Cash Flow and Investments - The net cash flow from operating activities decreased by 37.50% to CNY 68,453,222 from CNY 109,522,210 in 2021[19] - The company received government subsidies totaling CNY 3,928,995.50 in 2022, which are closely related to its normal business operations[24] - The company reported a financial expense reduction of 41.71%, resulting in a financial income of -¥1,569,331.57 for 2022[70] - Investment cash inflow decreased by 16.38% to ¥201,482,652.27, while net cash flow from investment activities improved by 96.80% to -¥1,715,400.76[76] - Financing cash inflow reached ¥50,000,000.00, with net cash flow from financing activities increasing by 146.61% to ¥27,592,000.02[75] - The company reported a significant decrease in investment amounting to ¥3,198,053.03, down 87.31% from ¥25,195,329.17 in the previous year[85] Market and Product Development - The company is focusing on optimizing its operational costs in response to ongoing healthcare reforms and procurement policies, which pose challenges to its business model[32] - The company anticipates continued growth in the pharmaceutical sector driven by increasing healthcare awareness and government investments in medical services[30] - The company is actively involved in the development of traditional Chinese medicine, with recent policies promoting the high-quality development of this sector[35] - The company has established partnerships for the development of new drugs, such as the Guo Liao Pi Injection (Xintong®) and Sodium Nifedipine Injection (Yimeifen®), enhancing its product portfolio[40] - The company is focused on optimizing production processes and reducing costs to improve product quality and efficiency in response to market pressures[34] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[134] - The company plans to enhance production capacity by building new production lines and improving production processes to support core product growth[95] - The company aims to strengthen partnerships with major pharmaceutical manufacturers and distributors to enhance its competitive position in the pharmaceutical distribution sector[95] Corporate Governance and Management - The company has established a complete internal audit system, ensuring the integrity and effectiveness of internal controls, with no fraud detected during the reporting period[107] - The financial department operates independently, with no shared bank accounts with controlling shareholders, and the company has a complete financial accounting system[112] - The company has a governance structure that includes a shareholders' meeting, board of directors, and supervisory board, all functioning independently[116] - The company has disclosed 52 announcements and 4 periodic reports, ensuring timely and accurate information for shareholders[106] - The company has a clear ownership structure, with all assets related to production and operations legally owned or controlled, ensuring no asset occupation by controlling shareholders[114] - The company has a history of significant management changes, indicating a dynamic approach to leadership and governance[122] - The company has appointed a new chairman and financial director, indicating a change in leadership and management structure[119] - The company is leveraging its experienced management team to drive growth and innovation in the pharmaceutical sector[124] Social Responsibility and Community Engagement - The company emphasizes corporate social responsibility, aiming to create maximum value for stakeholders while contributing to public health[98] - The company has actively communicated with stakeholders, aiming to balance interests and fulfill social responsibilities[108] - The company has implemented an employee stock ownership plan to enhance long-term motivation and share the company's growth with its employees[182] - The company has made significant contributions to local communities, including donations of agricultural production materials to assist impoverished households[184] - The company has maintained a strong commitment to corporate social responsibility, actively engaging in community support and poverty alleviation initiatives[184] - The company actively participated in poverty alleviation efforts, donating medicines and funds to assist impoverished communities in Tibet, including 100,000 yuan for housing repairs in Bai Rang Village[185] Environmental Compliance - The company has complied with environmental protection laws and standards, including the "Environmental Protection Law" and "Water Pollution Prevention Law" in 2022[170] - The company has obtained a national pollutant discharge permit, with the permit number 91510000620854656KP001, and submits quarterly and annual reports to the ecological environment bureau[170] - The company has been recognized as a "Good Environmental Protection Enterprise" by the Sichuan Provincial Department of Ecology and Environment during the reporting period[177] - The wastewater treatment system has a designed daily processing capacity of 450 tons, with an inflow COD concentration of approximately 3000 mg/L and an outflow COD concentration of around 45 mg/L, significantly below the standard of 300 mg/L[173] - The company invested a total of 1.2005 million yuan in environmental governance and protection in 2022, including an environmental protection tax payment of 640.93 yuan[177] Future Outlook and Strategic Goals - The company plans to distribute a cash dividend of CNY 1 per 10 shares, totaling CNY 19,067,775.00, based on a total share capital of 190,682,250 shares as of December 31, 2022[155] - The company has set a performance guidance of 10% revenue growth for the next fiscal year[134] - The company plans to adapt its sales model and enhance team personnel to promote performance recovery in 2023 as the economic environment gradually improves[193] - The company is focused on protecting investor interests and has outlined measures to address any potential losses incurred by investors[192] - The company projected net profits for the years 2021, 2022, 2023, and 2024 to be RMB 6 million, RMB 6.9 million, RMB 7.935 million, and RMB 9.12525 million respectively[195]

Financial Performance - The company's revenue for Q1 2023 was ¥171,430,742.25, a decrease of 8.05% compared to ¥186,434,809.99 in the same period last year[4] - Net profit attributable to shareholders was ¥8,363,504.12, down 1.93% from ¥8,528,415.37 year-on-year[4] - Total operating revenue for Q1 2023 was CNY 171,430,742.25, a decrease of 8.5% compared to CNY 186,434,809.99 in Q1 2022[28] - Net profit for Q1 2023 was CNY 8,478,872.65, slightly down by 1.9% from CNY 8,639,617.30 in Q1 2022[30] - The total comprehensive income for Q1 2023 was CNY 8,391,700.71, compared to CNY 8,637,294.56 in Q1 2022, indicating a decrease of 2.8%[30] Cash Flow - The net cash flow from operating activities increased significantly to ¥31,828,337.43, a 713.24% improvement from -¥5,190,203.15 in Q1 2022[10] - Cash inflow from operating activities increased to CNY 224,475,914.77 in Q1 2023, compared to CNY 211,295,382.30 in Q1 2022, reflecting a growth of 6.2%[32] - The net cash flow from investing activities was -¥100,219,757.00, which is a decline of ¥51,446,057.00 year-over-year[34] - The net cash flow from financing activities was -¥462,499.99, indicating no cash inflow from financing activities[34] - The net increase in cash and cash equivalents was -¥68,936,595.76, compared to a decrease of ¥56,638,556.05 in the previous period[35] - The ending balance of cash and cash equivalents was ¥207,346,181.35, down from ¥276,282,777.11 at the beginning of the period[35] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,015,182,951.21, a slight decrease of 0.30% from ¥1,018,204,645.88 at the end of the previous year[5] - The company's total liabilities decreased to CNY 256,795,042.24 in Q1 2023 from CNY 268,208,437.62 in Q1 2022, a reduction of 4.3%[26] - The total current assets as of March 31, 2023, amount to ¥578,091,376.85, slightly up from ¥575,009,326.03 at the beginning of the year[23] - The total assets of the company are ¥1,015,182,951.21, down from ¥1,018,204,645.88 at the beginning of the year[24] - The accounts receivable decreased from ¥162,609,114.23 to ¥129,932,347.05 during the reporting period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,848[12] - The largest shareholder, Gao Fan, holds 25.59% of shares, amounting to 48,800,382 shares, with 17,120,000 shares pledged[12] Investments and Expenses - Research and development expenses decreased by 51.49% to ¥498,451.91 from ¥1,027,543.70 in the same period last year[9] - The company reported a significant increase in credit impairment losses, which rose by 334.06% to ¥1,755,052.14 compared to a decrease of ¥749,839.71 in Q1 2022[9] - The company received government subsidies amounting to ¥582,278.88, which are closely related to its normal business operations[6] - The company has increased its short-term financial investments, with trading financial assets reaching ¥100,000,000.00, marking a 100% increase[9] - The company plans to invest $6,000,000 to acquire a 21.43% stake in Pier 88 Health Limited through its wholly-owned subsidiary TAPI Healthcare Inc.[15] Audit Information - The company did not undergo an audit for the first quarter report[36]

证券代码：002826 证券简称：易明医药 编号：2019-001 西藏易明西雅医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------|--------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | £ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | R 现场参观 | | | | □ 其他 | | | 参与单位名称及 人员姓名 | 银河证券、中投证券、东方财富等 | 27 名机构及个人投资者参会 | | 时间 | 2019 年 8 月 13 | 日 15:30-18:00 | | 地点 | 拉萨经济技术开发区林琼岗路 | 6 号西藏易明西雅医药科技股份 | | | 有限公司 | | | 上市公司接待人 | 董事、副董事长：周战先生 | | | 员姓名 | 副总经理、董事会秘书：许可先生 | | 1 / 3 | --- | --- | ...

1 证券代码：002826 证券简称：易明医药 编号：2021-001 西藏易明西雅医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Financial Performance - The company's revenue for Q3 2022 was ¥206,056,228.21, representing a 14.86% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥9,271,623.79, a 33.30% increase year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,074,465.58, up by 9.48% from the previous year[4] - The basic earnings per share for Q3 2022 was ¥0.05, a 25.00% increase compared to the same period last year[4] - Operating revenue for the first nine months of 2022 reached CNY 591.77 million, an increase of 14.21% compared to CNY 518.14 million in the same period of 2021[9] - Total operating revenue for Q3 2022 reached CNY 591,767,346.30, an increase of 14.2% compared to CNY 518,143,668.07 in Q3 2021[24] - Net profit for Q3 2022 was CNY 21,481,158.04, representing a 24.5% increase from CNY 17,172,369.51 in the same period last year[25] - Earnings per share (EPS) for Q3 2022 was CNY 0.11, compared to CNY 0.09 in Q3 2021, indicating a growth of 22.2%[26] Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥922,221,097.15, reflecting an 11.86% increase from the end of the previous year[4] - Total assets increased to CNY 922,221,097.15 from CNY 824,473,281.11, marking a rise of 11.8%[22] - Total liabilities rose to CNY 199,200,460.17, up from CNY 104,362,512.05, which is an increase of 90.8%[22] - The total equity attributable to shareholders at the end of Q3 2022 was ¥720,063,895.43, a slight increase of 0.37% from the previous year[4] - The total equity attributable to shareholders increased to CNY 720,063,895.43 from CNY 717,389,579.34, reflecting a slight growth of 0.4%[22] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥91,887,610.24, a 32.69% increase compared to the same period last year[4] - Net cash flow from operating activities increased by 32.69% to CNY 91.89 million, up from CNY 69.25 million year-on-year[10] - Operating cash flow for the current period was ¥91,887,610.24, an increase of 32.9% compared to ¥69,249,556.94 in the previous period[27] - Total cash inflow from operating activities was ¥721,398,791.01, down 25.3% from ¥965,164,381.49 in the previous period[27] - Cash outflow from operating activities totaled ¥629,511,180.77, a decrease of 29.7% compared to ¥895,914,824.55 in the previous period[27] - Cash received from investment recovery was ¥100,000,000.00, down from ¥210,000,000.00 in the previous period[29] - The ending cash and cash equivalents balance increased to ¥200,638,206.96 from ¥140,234,893.13 in the previous period[29] Accounts Management - The company reported a significant increase in accounts receivable, which rose by 140.92% to ¥88,232,258.49 compared to the end of 2021[8] - Accounts payable surged by 313.53% to CNY 64.81 million, up from CNY 15.67 million, driven by business growth and accrued promotional service fees[10] - Other receivables decreased by 64.63% to CNY 32.95 million, down from CNY 93.17 million, primarily due to changes in sales management and settlement methods[9] - Contract liabilities decreased by 84.44%, indicating a reduction in advance payments received compared to the previous year[10] Expenses and Investments - Research and development expenses decreased by 51.75% to CNY 3.34 million, down from CNY 6.93 million, due to the completion of a previous project[10] - The company reported a net cash outflow from investing activities of CNY 101.40 million, an increase of 83.67% compared to the previous year[10] - The company has committed to a total of ¥10,000,000 in wealth management products, all of which are backed by its own funds[16] - The company has invested in structured deposits with a reference annualized yield of 3.3%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,709[13] - The largest shareholder, Gao Fan, holds 26.40% of the shares, amounting to 50,335,682 shares, with 19,716,000 shares pledged[13] - The top ten shareholders do not have any disclosed relationships or agreements regarding concerted actions[13] Tax and Other Income - Income tax expenses increased by 47.22% to CNY 7.43 million, up from CNY 5.04 million, corresponding to profit growth[10] - Other comprehensive income increased by 148.53% to CNY 31.65 million, compared to a loss of CNY 65.23 million in the previous year[9] Audit Information - The company did not conduct an audit for the third quarter report[30]

Financial Performance - The company's revenue for the first half of 2022 was CNY 385,711,118.09, representing a 13.86% increase compared to CNY 338,753,077.45 in the same period last year[20]. - The net profit attributable to shareholders was CNY 11,973,982.43, up 17.65% from CNY 10,177,542.42 year-on-year[20]. - The net profit after deducting non-recurring gains and losses increased by 47.44%, reaching CNY 9,825,677.51 compared to CNY 6,664,384.22 in the previous year[20]. - The net cash flow from operating activities was CNY 41,365,880.80, a significant increase of 93.87% from CNY 21,337,384.56 in the same period last year[20]. - Basic earnings per share rose by 20.00% to CNY 0.06 from CNY 0.05[20]. - The total operating revenue for the first half of 2022 reached ¥385,711,118.09, an increase of 13.86% compared to ¥338,753,077.45 in the same period of 2021[154]. - Net profit for the first half of 2022 was ¥12,189,284.57, representing a 19.73% increase from ¥10,177,542.42 in the previous year[156]. - The total comprehensive income for the first half of 2022 was ¥12,178,369.13, compared to ¥10,168,627.70 in the previous year, marking a growth of 19.77%[157]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 860,957,592.60, reflecting a 4.43% increase from CNY 824,473,281.11 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 0.93%, amounting to CNY 710,684,478.20 compared to CNY 717,389,579.34 at the end of the previous year[20]. - Total liabilities rose to CNY 147,336,622.54, compared to CNY 104,362,512.05, marking an increase of around 41.1%[148]. - Current liabilities increased significantly to CNY 142,520,545.15 from CNY 99,346,853.50, a rise of approximately 43.4%[148]. - Cash and cash equivalents at the end of the reporting period amounted to ¥171,725,943.23, representing 19.95% of total assets, a decrease of 2.21% compared to the previous year[51]. - Accounts receivable increased to ¥91,388,139.85, accounting for 10.61% of total assets, up by 6.17% year-on-year due to a change in settlement methods from prepayment to credit sales[51]. - Inventory reached ¥38,824,820.44, which is 4.51% of total assets, reflecting a slight increase of 0.43% compared to the previous year[51]. Operational Highlights - The company maintained a 100% pass rate for finished products, adhering to quality management standards[34]. - The company’s main products, including Miglitol tablets and Hongjin Xiaojie tablets, experienced varying degrees of sales growth year-on-year[34]. - The company achieved a significant milestone with its α-glucosidase inhibitor, Miglitol tablets, being the first domestic generic version, maintaining the largest market share in China's Miglitol market[35]. - The company has established a strong market position in the production of raw materials, particularly for the drug Acetaminophen[31]. - The company is actively involved in the development of new products and technologies through collaborations with well-known pharmaceutical companies[32]. Risk Management - The company faces risks including reliance on specific product lines, industry policy risks, and economic environment impacts, which are detailed in the risk management section[5]. - The company is facing regulatory risks in the pharmaceutical industry, which may require enhanced operational compliance and cost control[71]. - The company acknowledges risks from the complex economic environment, including challenges in supply chain stability and raw material procurement[73]. Environmental and Social Responsibility - The wastewater treatment facility has a daily processing capacity of 450 tons, with treated COD levels significantly below the regulatory standard[83]. - The company has implemented a low-nitrogen combustion system in its boiler to effectively control nitrogen oxide emissions, ensuring compliance with environmental standards[83]. - The company has been recognized as an environmentally responsible enterprise by the Chengdu Ecological Environment Bureau during the reporting period[88]. - The company actively participates in poverty alleviation efforts, signing framework agreements with impoverished counties in Tibet and prioritizing employment for registered impoverished households[93]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company plans to repurchase and cancel 508,125 restricted shares due to unmet performance targets from the 2019 incentive plan[79]. - The total number of shares before the change was 191,190,375, with a decrease of 508,125 shares after the change, resulting in a total of 190,682,250 shares[125]. - The company has established an investor relations management system to enhance communication with investors, including a dedicated investor hotline and email[89]. - The company will closely monitor industry policy dynamics and strengthen operational management to ensure compliance and actively participate in national procurement[72].

证券代码：002826 证券简称：易明医药 编号：2022-028 西藏易明西雅医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 \n□ 现场参观 \n□ 其他 | □ 分析师会议 \n √ 业绩说明会 \n □ 路演活动 \n（请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 通过 " 全景 · 路演天下 " 上业绩说明会的投资者 | （ ...

Financial Performance - The company's revenue for Q1 2022 was CNY 186,434,809.99, representing a 17.84% increase compared to CNY 158,204,489.91 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 8,528,415.37, a significant increase of 62.16% from CNY 5,259,104.57 in Q1 2021[3] - Net profit for the period was CNY 8,639,617.30, representing a 64.4% increase from CNY 5,259,104.57 in Q1 2021[20] - The company reported a total comprehensive income of CNY 8,637,294.56 for the quarter, compared to CNY 5,265,796.80 in the same period last year[21] - Earnings per share (EPS) for the quarter was CNY 0.04, compared to CNY 0.03 in the previous year[21] Cash Flow - The net cash flow from operating activities improved to -CNY 5,190,203.15, a 47.09% reduction in losses compared to -CNY 9,808,758.10 in the previous year[3] - Cash flow from operating activities showed a net outflow of CNY -5,190,203.15, an improvement from CNY -9,808,758.10 in the same quarter last year[23] - Net cash flow from operating activities increased by 4,618,600 yuan compared to the same period last year, driven by performance growth[9] - Net cash flow from investing activities decreased by 32,166,600 yuan year-on-year, mainly due to the purchase of short-term principal-protected financial products amounting to 50 million yuan[9] - The net cash flow from investment activities was -51,446,057.00, indicating a significant outflow compared to the previous period[24] Assets and Liabilities - The company's total assets increased by 1.34% to CNY 835,486,086.66 from CNY 824,473,281.11 at the end of the previous year[3] - Total liabilities of the company were CNY 106,547,197.12, compared to CNY 104,362,512.05 in the previous period[20] - The total equity attributable to shareholders of the parent company was CNY 726,106,208.19, an increase from CNY 717,389,579.34[20] - Cash and cash equivalents decreased from 182,725,241.42 yuan at the beginning of the year to 126,392,276.12 yuan by the end of the reporting period[16] - The total cash and cash equivalents at the end of the period were 125,332,253.38, down from 181,970,809.43 at the beginning of the period[24] Expenses - Research and development expenses decreased by 79.64% to CNY 1,027,543.70, as the previous year's project concluded[8] - Research and development expenses decreased to CNY 1,027,543.70 from CNY 5,046,997.60, indicating a significant reduction in R&D spending[20] - Sales expenses increased by 52.97% to CNY 57,372,964.22, driven by higher marketing and promotional activities[8] - Sales expenses increased to CNY 57,372,964.22, up from CNY 37,506,799.99, marking a rise of 53.0% year-over-year[20] Accounts Receivable and Impairment - Accounts receivable increased by 179.21% to CNY 102,254,279.28, primarily due to changes in sales management and settlement methods[7] - Accounts receivable increased significantly from 36,622,988.75 yuan at the beginning of the year to 102,254,279.28 yuan by the end of the reporting period[16] - Credit impairment losses increased by 759,000 yuan year-on-year, primarily due to an increase in receivables and the corresponding increase in credit impairment losses[9] Shareholder Information - The company had a total of 16,982 common shareholders at the end of the reporting period[11] - The largest shareholder, Gao Fan, holds 26.66% of the shares, with 20,486,000 shares pledged[11] Other Income and Subsidies - The company received government subsidies amounting to CNY 563,592.94 related to employee training during the reporting period[5] - The company reported a significant increase in other income, which rose by 341.95% to CNY 570,349.21, reflecting improved operational performance[8] Financial Management - The company has no plans for future high-risk entrusted financial management as of the reporting period[15] - The company did not undergo an audit for the first quarter report[25]

Financial Performance - The company's operating revenue for 2021 was ¥725,459,075.46, representing a 20.38% increase compared to ¥602,619,263.55 in 2020[21] - The net profit attributable to shareholders for 2021 was ¥42,476,491.18, a 3.37% increase from ¥41,091,164.30 in 2020[21] - The net profit after deducting non-recurring gains and losses was ¥38,634,658.44, which is a 21.29% increase from ¥31,854,012.56 in 2020[21] - The net cash flow from operating activities was ¥109,522,210.40, up 7.65% from ¥101,735,689.50 in 2020[21] - The total assets at the end of 2021 were ¥824,473,281.11, a decrease of 9.21% from ¥908,087,426.76 at the end of 2020[21] - The net assets attributable to shareholders increased by 4.40% to ¥717,389,579.34 from ¥687,146,488.90 at the end of 2020[21] - The basic earnings per share remained at ¥0.22, unchanged from 2020[21] - The weighted average return on equity was 6.06%, slightly down from 6.14% in 2020[21] Revenue Breakdown - The cardiovascular segment generated ¥332,312,173.43, accounting for 45.81% of total revenue, with a year-on-year growth of 31.12%[54] - The diabetes segment reported revenue of ¥190,065,053.82, which is 26.20% of total revenue, reflecting a growth of 27.21% year-on-year[54] - The gynecology segment saw a decline in revenue to ¥105,986,219.62, down 14.67% from the previous year[54] - The North China region achieved revenue of ¥139,941,812.64, a significant increase of 58.45% compared to the previous year[54] - The total revenue from the distribution model was ¥321,907,648.54, which is 44.37% of total revenue, marking a growth of 34.36% year-on-year[55] Market and Product Strategy - The company has identified the development of innovative drugs as a key strategic direction, supported by recent regulatory reforms that encourage faster drug approval processes[34] - The company is focusing on optimizing product quality and cost control in response to the challenges posed by the DRG payment reform, which is set to be fully implemented by 2025[32] - The company is engaged in both self-produced and third-party cooperative pharmaceutical businesses, leveraging its resources to create diverse business models[35] - The company plans to actively participate in national drug centralized procurement to increase market share and revenue from products undergoing consistency evaluation[118] Research and Development - Research and development expenses rose by 66.33% to ¥11,390,280.90, reflecting the company's commitment to advancing its R&D initiatives[66] - The total research and development investment was ¥9,313,942.01, which accounted for 1.28% of operating revenue, down from 1.58% in 2020[70] - Ongoing research and development efforts are set to increase, with a budget allocation of 80 million RMB for new technology advancements in the pharmaceutical sector[141] Corporate Governance - The company has established a governance structure including a board of directors, supervisory board, and various specialized committees, ensuring compliance with relevant regulations[125] - The board of directors consists of three independent directors, meeting the requirement of more than one-third of the total board members[126] - The company has a dedicated internal audit department that supervises the integrity and effectiveness of internal controls, with no fraud detected during the reporting period[128] - The company has maintained financial independence, with a complete financial accounting system and independent tax registration, ensuring no shared bank accounts with controlling shareholders[131] Social Responsibility and Environmental Initiatives - The company has made significant contributions to social responsibility, including donations of medicines to disaster-stricken areas and support for impoverished communities[52] - The company has implemented various environmental protection measures, including upgrading wastewater monitoring and reducing ammonia water usage by 80%[50] - The company has been recognized as an environmentally trustworthy enterprise by the Chengdu Ecological Environment Bureau[193] - The company actively engaged in poverty alleviation efforts, signing framework agreements with multiple impoverished counties in Tibet and providing direct assistance such as scholarships and living subsidies[200] Employee Engagement and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.3628 million[151] - The company has a remuneration decision-making process involving the remuneration and assessment committee, which requires board approval and shareholder meeting ratification[149] - The company provided various training opportunities to enhance employee development and satisfaction, fostering a harmonious labor relationship[199] Strategic Acquisitions - The company completed the acquisition of 51% of Inner Mongolia Bostai's shares, which is expected to become a new growth point for performance[48] - The company acquired a 51% stake in Inner Mongolia Bostai Enterprise Management Co., Ltd., with plans for integration and management oversight to align with company standards[178] Financial Management - The company reported a significant increase in inventory, which rose to CNY 33,608,165.62, representing 4.08% of total assets, compared to 2.28% in the previous year[78] - The company has established a comprehensive budget management system to enhance cost awareness and optimize resource allocation[49] - The company reported a total cash inflow from operating activities of ¥923,918,208.06 in 2021, a 20.50% increase compared to ¥766,738,008.28 in 2020[72]